Hepatitis A in the era of vaccination

Epidemiologic Reviews

Volumn 28, Issue 1, 2006, Pages 101-111

  Wasley, Annemarie ^a   Fiore, Anthony ^a   Bell, Beth P ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Hepatitis A; Hepatitis A vaccine; Hepatitis A virus; Vaccines

Indexed keywords

HEPATITIS A HEPATITIS B VACCINE; HEPATITIS A VACCINE; IMMUNOGLOBULIN;

ANTIBODY TITER; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUCED HEADACHE; ENDEMIC DISEASE; HEALTH CARE; HEPATITIS A; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; INCIDENCE; INFECTION CONTROL; INJECTION SITE REACTION; MALAISE; PRIORITY JOURNAL; REVIEW; SEROPREVALENCE; SOCIOECONOMICS; STATISTICAL SIGNIFICANCE; UNITED STATES; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

CHILD, PRESCHOOL; HEPATITIS A; HEPATITIS A VACCINES; HUMANS; IMMUNITY, HERD; IMMUNIZATION PROGRAMS; UNITED STATES; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 33747886035     PISSN: 0193936X     EISSN: 14786729     Source Type: Journal    
DOI: 10.1093/epirev/mxj012     Document Type: Review

References (125)

1. Havens WP Jr. Immunity in experimentally induced infectious hepatitis. J Exp Med 1946;84:403-6.
2. Neefe JR, Gellis SS, Stokes J Jr. Homologous serum hepatitis and infectious (epidemic) hepatitis; studies in volunteers bearing on immunological and other characteristics of the etiological agents. Am J Med 1946;1:3-22.
3. Bachman L. Infectious hepatitis in Europe. In: Rodenwaldt E, ed. World atlas of epidemic diseases. Hamburg, Germany: Falk-Verlag, 1952:67-71.
4. World Health Organization. Hepatitis A vaccines. Wkly Epidemiol Rec 2000;75:38-44.
5. Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol Infect 2004;132:1005-22.
6. Krugman S, Giles JP. Viral hepatitis: new light on an old disease. JAMA 1970;212:1019-29.
7. Hadler SC, Webster HM, Erben JJ, et al. Hepatitis A in daycare centers: a community-wide assessment. N Engl J Med 1980;302:1222-7.
8. Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985;122:226-33.
9. Poovorawan Y, Theamboonlers A, Chongsrisawat V, et al. Clinical features and molecular characterization of hepatitis A virus outbreak in a child care center in Thailand. J Clin Virol 2005;32:24-8.
10. Glikson M, Galun E, Oren R, et al. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 1992;71:14-23.
11. Centers for Disease Control and Prevention. Hepatitis surveillance report no. 60. Atlanta, GA: Centers for Disease Control and Prevention, 2005. (http://www.cdc.gov/ncidod/diseases/hepatitis/resource/PDFs/hep_surveillance_60. pdf).
12. Vento S, Garofano T, Renzini C, et. al. Acute liver failure associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
13. Akriviadis EA, Redeker AG. Fulminant hepatitis A in intravenous drug users with chronic liver disease. Ann Intern Med 1989;110:838-9.
14. Tassopoulos NC, Papaevangelou GJ, Ticehurst JR, et al. Fecal excretion of Greek strains of hepatitis A virus in patients with hepatitis A and in experimentally infected chimpanzees. J Infect Dis 1986;154:231-7.
15. Sjogren MH, Tanno H, Fay O, et al. Hepatitis A virus in stool during clinical relapse. Ann Intern Med 1987;106:221-6.
16. Rosenblum LS, Villarino ME, Nainan OV, et al. Hepatitis A outbreak in a neonatal intensive care unit: risk factors for transmission and evidence of prolonged viral excretion among preterm infants. J Infect Dis 1991;164:476-82.
17. Robertson BH, Averhoff F, Cromeans TL, et al. Genetic relatedness of hepatitis A virus isolates during a community-wide outbreak. J Med Virol 2000;62:144-50.
18. Bell BP, Shapiro CN, Alter MJ, et al. The diverse patterns of hepatitis A epidemiology in the United States - implications for vaccination strategies. J Infect Dis 1998;178:1579-84.
19. Staes CJ, Schlenker TL, Risk I, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics 2000;106:E54. (Electronic article).
20. Nainan OV, Armstrong GL, Han X-H, et al. Hepatitis A molecular epidemiology in the United States, 1996-1997: sources of infection and implications of vaccination policy. J Infect Dis 2005;191:957-63.
21. Vong S, Fiore AE, Haight DO, et al. Vaccination in the county jail as a strategy to reach high risk adults during a community-based hepatitis A outbreak among methamphetamine drug users. Vaccine 2005;23:1021-8.
22. Hutin YJ, Bell BP, Marshall KL, et al. Identifying target groups for a potential vaccination program during a hepatitis A community-wide outbreak. Am J Public Health 1999;89:918-21.
23. Cotter SM, Sansom S, Long T, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis 2003;187:1235-40.
24. Carl M, Francis DP, Maynard JE. Food-borne hepatitis A: recommendations for control. J Infect Dis 1983;148:1133-5.
25. Fiore AE. Hepatitis A transmitted by food. Clin Infect Dis 2004;38:705-15.
26. Hutin YJF, Pool V, Cramer EH, et al. A multistate outbreak of hepatitis A. N Engl J Med 1999;340:595-602.
27. Wheeler C, Vogt T, Armstrong GL, et al. A foodborne outbreak of hepatitis A in Pennsylvania associated with green onions. N Engl J Med 2005;353:890-7.
28. Rosenblum LS, Mirkin IR, Allen DT, et al. A multifocal outbreak of hepatitis A traced to commercially distributed lettuce. Am J Public Health 1990;80:1075-9.
29. Desenclos JA, Klontz KC, Wilder MH, et al. A multistate outbreak of hepatitis A caused by the consumption of raw oysters. Am J Public Health 1991;81:1268-72.
30. Halliday ML, Kang LY, Zhou TK, et al. An epidemic of hepatitis A attributable to the ingestion of raw clams in Shanghai, China. J Infect Dis 1991;164:852-9.
31. Lemon SM. The natural history of hepatitis A: the potential for transmission by transfusion of blood or blood products. Vox Sang 1994;67(suppl 4):19-23.
32. Mannuci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. Ann Intern Med 1994;120:1-7.
33. Hollinger FB, Kirtava A, Oakley M, et al. Blood safety monitoring among persons with bleeding disorders - United States, May 1998-June 2002. MMWR Morb Mortal Wkly Rep 2003;51:1152-4.
34. Stapleton JT. Host immune response to hepatitis A virus. J Infect Dis 1995;171(suppl 1):S9-14.
35. Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology 1984;4:933-6.
36. Dembek ZF, Hadler JF, Castrodale L, et al. Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis - United States, 2002-2004. MMWR Morb Mortal Wkly Rep 2005;54:453-6.
37. Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis 1992;14:580-6.
38. Stokes J, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin: preliminary note. JAMA 1945;127:144-5.
39. Ashur Y, Adler R, Rowe M, et al. Comparison of immunogenicity of two hepatitis A vaccines - VAQTA and HAVRIX - in young adults. Vaccine 1999;17:2290-6.
40. Bryan JP, Henry CH, Hoffman AG, et al. Randomized, crossover, controlled comparison of two inactivated hepatitis A vaccines. Vaccine 2001;19:743-50.
41. Connor BA, Phair J, Sack D, et al. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix. Clin Infect Dis 2001;32:396-401.
42. Castillo De Febres O, Chacon de Petrola M, Casanova de Escalaona L, et al. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4-15 year old children. Vaccine 1999;18:656-64.
43. Riedemann S, Reinhardt G, Ibarra H, et al. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxalreg;) in healthy toddlers and children in Chile. Acta Paediatr 2004;93:412-14.
44. Ambrosch F, Wiedermann G, Jonas S, et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine 1997;15:1209-13.
45. Lemon SM. Immunologic approaches to assessing the response to inactivated hepatitis A vaccine. J Hepatol 1993;18(suppl 2):S15-19.
46. Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol 1993;18(suppl 2):S51-5.
47. Clemens R, Safary A, Hepburn A, et al. Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995;171(suppl 1):S44-9.
48. McMahon BJ, Williams J, Bulkow L, et al. Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995;171:676-9.
49. Knoll A, Hottentrager B, Kainz J, et al. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults. Vaccine 2000;18:2029-32.
50. Czeschinski PA, Binding N, Witting U. Hepatitis A and hepatitis B vaccinations: immunogenicity of combined vaccine and of simultaneously or separately applied single vaccines. Vaccine 2000;18:1074-80.
51. Balcarek KB, Bagley MR, Pass RF, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995;171(suppl 1):S70-2.
52. Horng YC, Chang MH, Lee CY, et al. Safety and immunogenicity of hepatitis A vaccine in healthy children. Pediatr Infect Dis J 1993;12:359-62.
53. Letson GW, Shapiro CN, Kuehn D, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004;144:327-32.
54. Dagan R, Amir J, Mijalovsky A, et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000;19:1045-52.
55. Williams JL, Bruden DA, Cagle HH, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine 2003;21:3208-11.
56. Iwarson S, Lindh M, Widerstrom L. Excellent booster response 4 to 8 years after a single primary dose of an inactivated hepatitis A vaccine. J Travel Med 2004;11:120-1.
57. Usonis V, Meriste S, Bakasenas V, et al. Immunogenicity and safety of a combined hepatitis A and B vaccine administered concomitantly with either a measles-mumps-rubella or a diphtheria-tetanus-acellular pertussis-inactivated poliomyelitis vaccine mixed with a Haemophilus influenzae type b conjugate vaccine in infants aged 12-18 months. Vaccine 2005;23:2602-6.
58. Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA 1994;271:28-34.
59. Werzberger A, Mensch B, Kuter B, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N Engl J Med 1992;327:453-7.
60. Sagliocca L, Amoroso P, Stroffolini T, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet 1999;353:1136-9.
61. Werzberger A, Mensch B, Nalin DR, et al. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA. Vaccine 2002;20:1699-701.
62. Werzberger A, Kuter B, Nalin D, et al. Six years follow-up after hepatitis A vaccination. (Letter). N Engl J Med 1998;338:1160.
63. Van Herck K, Van Damme P, Lievens M, et al. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol 2004;72:194-6.
64. Van Damme P, Banatvala J, Fay O, et al. Hepatitis A booster vaccination: is there a need? Lancet 2003;362:1065-71.
65. Wagner G, Lavanchy D, Darioli R, et al. Simultaneous active and passive immunization against hepatitis A studied in a population of travelers. Vaccine 1993;11:1027-32.
66. Walter EB, Hornick RB, Poland GA, et al. Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine 1999;17:1468-73.
67. Fiore AE, Shapiro CN, Sabin K, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J 2003;22:354-9.
68. Kanra G, Yalcin SS, Kara A, et al. Hepatitis A booster vaccine in children after infant immunization. Pediatr Infect Dis J 2002;21:727-30.
69. Lieberman J, Chang S-J, Partridge S, et al. Kinetics of maternal hepatitis A antibody decline in infants: implications for vaccine use. Pediatr Infect Dis J 2002;21:347-8.
70. Bell BP, Negus S, Fiore AE, et al. A comparison of the effect of age on hepatitis A vaccine immunogenicity among infants with and without passively transferred maternal antibody. (Abstract 756). Presented at the 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, Illinois, October 24-27, 2002.
71. Wallace MR, Brandt CJ, Earhart KC, et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004;39:1207-13.
72. Kemper CA, Haubirch R, Frank I, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis 2003;187:1327-31.
73. Gouvea AF, de Moraes-Pinto MI, Ono E, et al. Immunogenicity and tolerability of hepatitis A vaccine in HIV-infected children. Clin Infect Dis 2005;41:544-8.
74. Nielsen GA, Bodsworth NJ,Watts N. Response to hepatitis A vaccination in human immunodeficiency virus-infected and -uninfected homosexual men. J Infect Dis 1997;176:1064-7.
75. Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS 2005;19:1702-4.
76. Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol 2003;37:258-61.
77. Majda-Stanislawa E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J 2004;23:571-3.
78. Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999;94:1601-4.
79. Arslan M, Wiesner RH, Poterucha JJ, et al. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001;72:272-6.
80. Stark K, Gunther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 1999;180:2014-17.
81. Briem H, Safary A. Immunogenicity and safety in adults of hepatitis A virus vaccine administered as a single dose with a booster 6 months later. J Med Virol 1994;44:443-5.
82. GlaxoSmithKline Biologicals. HAVRIXreg;. (Package insert). Rixensart, Belgium: GlaxoSmithKline Biologicals, 2005.
83. Merck & Company, Inc. VAQTA®. (Package insert). Whitehouse Station, NJ: Merck & Company, Inc, 2005.
84. Black S, Shinefield H, Hansen J, et al. A post-licensure evaluation of the safety of inactivated hepatitis A vaccine (Vaqta, Merck) in children and adults. Vaccine 2004;22:766-72.
85. Niu MT, Salive M, Krueger C, et al. Two-year review of hepatitis A vaccine safety: data from the Vaccine Adverse Event Reporting System (VAERS). Clin Infect Dis 1998;26:1475-6.
86. Bell BP. Global epidemiology of hepatitis A: implications for control strategies. In: Margolis HS, Alter MJ, Liang JT, et al, eds. Viral hepatitis and liver disease. London, United Kingdom: International Medical Press Ltd, 2002:359-65.
87. Hadler SC. Global impact of hepatitis A virus infection: changing patterns. In: Hollinger FB, Lemon SM, Margolis HS, eds. Viral hepatitis and liver disease. Baltimore, MD: Williams & Wilkins, 1991:14-20.
88. Coursaget P, Leboulleux D, Gharbi Y, et al. Etiology of acute sporadic hepatitis in adults in Senegal and Tunisia. Scand J Infect Dis 1995;27:9-11.
89. Tsega E, Mengesha B, Hansson BG, et al. Hepatitis A, B, and delta infection in Ethiopia: a serologic survey with demographic data. Am J Epidemiol 1986;123:344-51.
90. Cianciara J. Hepatitis A shifting epidemiology in Poland and Eastern Europe. Vaccine 2000;18(suppl 1):S68-70.
91. Green MS, Block C, Slater PE. Rise in the incidence of viral hepatitis in Israel despite improved socioeconomic conditions. Rev Infect Dis 1989;11:464-9.
92. Gil A, Gonzalez A, Dal Re R, et al. Prevalence of antibodies against varicella zoster, herpes simplex (types 1 and 2), hepatitis B and hepatitis A viruses among Spanish adolescents. J Infect 1998;36:53-6.
93. Shapiro CN, Coleman PJ, McQuillan GM, et al. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 1992;10(suppl 1):S59-62.
94. Prodinger WM, Larcher C, Solder BM, et al. Hepatitis A in Western Austria - the epidemiological situation before the introduction of active immunisation. Infection 1994;22:53-5.
95. Termorshuizen F, Dorigo-Zetsma JW, de Melker HE, et al. The prevalence of antibodies to hepatitis A virus and its determinants in the Netherlands: a population-based survey. Epidemiol Infect 2000;124:459-66.
96. Bottiger M, Christenson B, Grillner L. Hepatitis A immunity in the Swedish population. A study of the prevalence of markers in the Swedish population. Scand J Infect Dis 1997;29:99-102.
97. Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 2002;109:839-45.
98. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999;48:1-37.
99. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1996;45:1-30.
100. Cotter SM, Sansom S, Lee B, et al. Risk factors for hepatitis A among men who have sex with men, Ohio, 1998-1999. Antivir Ther 2000;5(suppl 1):A.6.
101. Friedman MS, Blake PA, Koehler JE, et al. Factors influencing a community-wide campaign to administer hepatitis A vaccine to men who have sex with men. Am J Public Health 2000;90:1942-6.
102. Harkess J, Gildon B, Istre GR. Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87. Am J Public Health 1989;79:463-6.
103. Ivie K, Spruill C, Bell BP. Prevalence of hepatitis A virus infection among illicit drug users, 1993-1994. (Abstract A010). Antivir Ther 2000;5(suppl 1):A.7.
104. Villano SA, Nelson KE, Vlahov D, et al. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis 1997;25:726-8.
105. Katz MH, Hsu L, Wong E, et al. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. J Infect Dis 1997;175:1225-9.
106. Crowcroft N, Walsh B, Davison KL, et al. Guidelines for the control of hepatitis A virus infection. Commun Dis Public Health 2001;4:213-27.
107. Franco E, Giambi C, Ialacci R, et al. Risk groups for hepatitis A virus infection. Vaccine 2003;21:2224-33.
108. National Advisory Committee on Immunizations, Public Health Agency of Canada. Hepatitis A vaccine. In: Canadian immunization guide. 6th ed. Ottawa, Ontario, Canada: Public Health Agency of Canada, 2002:93-101. (http://www.phac-aspc.gc.ca/publicat/cig-gci/#toc).
109. Steffen R, Kane MA, Shapiro CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA 1994;272:885-9.
110. Germinario C, Lopalco PL, Chicanna M, et al. From hepatitis B to hepatitis A and prevention: the Puglia (Italy) experience. Vaccine 2000;18(suppl):S83-5.
111. Lopalco PL, Salleras L, Barbuti S, et al. Hepatitis A and B in children and adolescents - what can we learn from Puglia (Italy) and Catalonia (Spain)? Vaccine 2001;19:470-4.
112. Diel R, Schneider S: Transmission of hepatitis A in Hamburg, Germany, 1998-1999 - a prospective population based study. Eur J Epidemiol 2001;17:175-82.
113. Van Gorkom J, Leentvaar-Kuijpers A, Kool JL, et al. Annual epidemics of hepatitis A in four large cities related to holiday travel among immigrant children. (In Dutch). Ned Tijdschr Geneesk 1998;142:1919-23.
114. Weinberg M, Hopkins J, Farrington L, et al. Hepatitis A in Hispanic children who live along the United States-Mexico border: the role of international travel and food-borne exposures. Pediatrics 2004;114:e68-73. (Electronic article).
115. Averhoff F, Shapiro CN, Bell BP, et al. Control of hepatitis A through routine vaccination of children. JAMA 2001;286:2968-73.
116. American Academy of Pediatrics. Hepatitis A. In: Pickering LK, ed. Red book: 2003 report of the Committee on Infectious Diseases. Elk Grove Village, IL: American Academy of Pediatrics, 2003:309-18.
117. Dagan R, Leventhal A, Anis E, et al. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 2005;294:202-10.
118. MacIntype CR, Burgess MA, McIntyre PB. Hepatitis A vaccination options for Australia. J Paediatr Child Health 2003;39:83-7.
119. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-24.
120. Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005;294:194-201.
121. Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995-2001. Vaccine 2004;22:4342-50.
122. Hepatitis Avaccination coverage among children aged 24-35 months - United States, 2003. MMWR Morb Mortal Wkly Rep 2005;54:141-14.
123. Amon JJ, Darling N, Fiore AE, et al. Factors associated with hepatitis Avaccination among children 24-35 months of age: United States, 2003. Pediatrics 2006;117:30-3.
124. Dominguez A, Salleras L, Carmona G, et al. Effectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 2003;21:698-701.
125. Bell BP, Anderson DA, Feinstone SM. Hepatitis A virus. In: Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. 6th ed. London, United Kingdom: Churchill Livingstone, 2005:2162-83.